Overview

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.

Phase:

Phase 2

Details

Lead Sponsor:

Daiichi Sankyo, Inc.

Collaborator:

Daiichi Sankyo Co., Ltd.

Treatments:

Antibodies, Monoclonal
Patritumab deruxtecan